Arsenic-induced cutaneous hyperplastic lesions are associated with the dysregulation of Yap, a Hippo signaling-related protein

Biochemical and Biophysical Research Communications

Volumn 438, Issue 4, 2013, Pages 607-612

  Li, Changzhao ^a   Srivastava, Ritesh K ^a   Elmets, Craig A ^a   Afaq, Farrukh ^a   Athar, Mohammad ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Arsenic; Carcinogenesis; Hippo signaling pathway; Yap

Indexed keywords

ALPHA CATENIN; ANKRD1 PROTEIN; ARSENIC; CONNECTIVE TISSUE GROWTH FACTOR; CYSTEINE RICH PROTEIN 61; MOB1 PROTEIN; PROTEIN; REGULATOR PROTEIN; SAV1 PROTEIN; TRANSCRIPTION FACTOR GLI2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL JUNCTION; CONTROLLED STUDY; DISEASE ASSOCIATION; EMBRYO DEVELOPMENT; EPIDERMIS; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; ORGAN SIZE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN DEFECT; UPREGULATION; WESTERN BLOTTING;

AMOTL1; ANGIOMOTIN-LIKE 1; ARSENIC; BASAL CELL CARCINOMA; BCC; CARCINOGENESIS; HIPPO SIGNALING PATHWAY; LARGE TUMOR SUPPRESSOR KINASE 1/2; LATS1/2; MAMMALIAN STE20-LIKE KINASE 1/2; MOB KINASE ACTIVATOR 1A; MOB1; MST1/2; SALVADOR HOMOLOG 1; SAV1; SCC; SQUAMOUS CELL CARCINOMA; TAZ; TEA-DOMAIN; TEAD; TRANSCRIPTIONAL CO-ACTIVATOR WITH PDZ-BINDING MOTIF; YAP; YES-ASSOCIATED PROTEIN;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ARSENIC; MICE; MICE, HAIRLESS; PHOSPHOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; SKIN; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

MURINAE; MUS;

EID: 84883299356     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.08.008     Document Type: Article

References (22)

1. Argos M., Kalra T., Rathouz P.J., Chen Y., Pierce B., Parvez F., Islam T., Ahmed A., Rakibuz-Zaman M., Hasan R., Sarwar G., Slavkovich V., van Geen A., Graziano J., Ahsan H. Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort study. Lancet 2010, 376:252-258.
2. Tseng C.H. Arsenic exposure and diabetes mellitus in the United States. JAMA 2008, 300:2728. author reply 2728-2729.
3. Wu M.M., Kuo T.L., Hwang Y.H., Chen C.J. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am. J. Epidemiol. 1989, 130:1123-1132.
4. Alain G., Tousignant J., Rozenfarb E. Chronic arsenic toxicity. Int. J. Dermatol. 1993, 32:899-901.
5. Halder G., Johnson R.L. Hippo signaling: growth control and beyond. Development 2011, 138:9-22.
6. Zhao B., Ye X., Yu J., Li L., Li W., Li S., Lin J.D., Wang C.Y., Chinnaiyan A.M., Lai Z.C., Guan K.L. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008, 22:1962-1971.
7. Oka T., Remue E., Meerschaert K., Vanloo B., Boucherie C., Gfeller D., Bader G.D., Sidhu S.S., Vandekerckhove J., Gettemans J., Sudol M. Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. Biochem. J. 2010, 432:461-472.
8. Schlegelmilch K., Mohseni M., Kirak O., Pruszak J., Rodriguez J.R., Zhou D., Kreger B.T., Vasioukhin V., Avruch J., Brummelkamp T.R., Camargo F.D. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 2011, 144:782-795.
9. Lignitto L., Arcella A., Sepe M., Rinaldi L., Delle Donne R., Gallo A., Stefan E., Bachmann V.A., Oliva M.A., Tiziana Storlazzi C., L'Abbate A., Brunetti A., Gargiulo S., Gramanzini M., Insabato L., Garbi C., Gottesman M.E., Feliciello A. Proteolysis of MOB1 by the ubiquitin ligase praja2 attenuates Hippo signalling and supports glioblastoma growth. Nat. Commun. 2013, 4:1822.
10. Salah Z., Melino G., Aqeilan R.I. Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity. Cancer Res. 2011, 71:2010-2020.
11. Halder G., Dupont S., Piccolo S. Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat. Rev. Mol. Cell Biol. 2012, 13:591-600.
12. Li C., Xu J., Li F., Chaudhary S.C., Weng Z., Wen J., Elmets C.A., Ahsan H., Athar M. Unfolded protein response signaling and MAP kinase pathways underlie pathogenesis of arsenic-induced cutaneous inflammation. Cancer Prev. Res. (Phila) 2011, 4:2101-2109.
13. Hao Y., Chun A., Cheung K., Rashidi B., Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J. Biol. Chem. 2008, 283:5496-5509.
14. Zhao B., Tumaneng K., Guan K.L. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat. Cell Biol. 2011, 13:877-883.
15. Kitchin K.T. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol. 2001, 172:249-261.
16. Yu H.S., Liao W.T., Chai C.Y. Arsenic carcinogenesis in the skin. J. Biomed. Sci. 2006, 13:657-666.
17. Wong E.W., Sun S., Li M.W., Lee W.M., Cheng C.Y. 14-3-3 Protein regulates cell adhesion in the seminiferous epithelium of rat testes. Endocrinology 2009, 150:4713-4723.
18. Ling C., Zuo D., Xue B., Muthuswamy S., Muller W.J. A novel role for 14-3-3sigma in regulating epithelial cell polarity. Genes Dev. 2010, 24:947-956.
19. Wang C., An J., Zhang P., Xu C., Gao K., Wu D., Wang D., Yu H., Liu J.O., Yu L. The Nedd4-like ubiquitin E3 ligases target angiomotin/p130 to ubiquitin-dependent degradation. Biochem. J. 2012, 444:279-289.
20. Skouloudaki K., Walz G. YAP1 recruits c-Abl to protect angiomotin-like 1 from Nedd4-mediated degradation. PLoS One 2012, 7:e35735.
21. Zhao B., Li L., Lei Q., Guan K.L. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010, 24:862-874.
22. Guo H.R., Yu H.S., Hu H., Monson R.R. Arsenic in drinking water and skin cancers: cell-type specificity (Taiwan, ROC). Cancer Causes Control 2001, 12:909-916.